BIOTRIP, the independent biotech incubator from TU Eindhoven and Radboudumc, presents the vision for its biotech incubator in its first animation. BIOTRIP will officially launch on January 1st, 2022.
For more on BIOTRIP, read more on how Radboudumc and Eindhoven University of Technology come together in BIOTRIP (in Dutch).
Related news items
Simmunext: where immunotherapy and chemistry meet
2 June 2022The story behind Radboud university medical center’s, Radboud University’s and Oncode’s newest spinoff, Simmunext Biotherapeutics B.V.
read more
T-Guard can reset immune system
1 December 2021For 20 years, the Nijmegen based Radboudumc spin-off company Xenikos has been working on a drug that can reset the immune system. This reset will save lives of seriously ill patients. Now, after years of hard work, the moment of truth has arrived for T-guard.
read more
Sonlicromanol seems promising for certain cancers Khondrion announces publication in PLOS ONE of new research
13 July 2021Khondrion announces publication in PLOS ONE of new research showing normalisation of prostate cancer stem cell mPGES-1 overexpression and inhibition of cancer spheroid growth by sonlicromanol’s active metabolite.
read more
Teaming up to develop an effective cure for mycobacterium abscessus disease using inhaled tigecycline
7 July 2021PureIMS, Radboudumc, and Sever Pharma Solutions are now teaming up to develop an effective cure for this chronic and debilitating disease.
read more
Radboudumc and Eindhoven University of Technology join forces in BIOTRIP Biotech incubator to deliver the vaccines and immunotherapies of the future.
1 July 2021BIOTRIP is a unique platform aimed at developing, commercializing, and making available of vaccins and immunotherapies.
read more
Radboudumc and Radboud University strengthen collaboration with Janssen
17 March 2019On March 12, Radboudumc and Radboud University have signed a letter of intent for intensified collaboration with Janssen.
read more